• Avaí Bio reached terms with Austrianova on a collaboration with an unnamed international partner to supply insulin-producing cells for Insulinova.
• Insulinova, formed in late 2025, is a joint venture between Avaí Bio and Austrianova to develop an implantable diabetes cell therapy.
• The program pairs programmed insulin-producing cells with Austrianova’s Cell-in-a-Box encapsulation technology to enable glucose-responsive insulin production.
• Definitive agreements remain subject to execution, with closing conditions expected to be completed in the coming days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avai Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607210800PR_NEWS_USPR_____LN08867) on July 21, 2026, and is solely responsible for the information contained therein.